No Data
No Data
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Barclays Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $76
Analysts' Opinions Are Mixed on These Healthcare Stocks: Healthequity (HQY), Community Health (CYH) and Gilead Sciences (GILD)
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
Gilead Sciences Says Lenacapavir 'Highly Effective' in HIV Prevention in Phase 3 Study
Express News | Gilead Sciences Announced Phase 3 Purpose 1 Trial Data, Showing Zero Infections And 100% Efficacy And Superiority Of Lenacapavir To Background HIV Incidence For The Investigational Use Of HIV Prevention In Cisgender Women
No Data
Supermengg :![+1 👍](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f44d.png)
103397071 : good
73958256 : translate
Paul Anthony : visit Singapore coming up
Paul Anthony : for young people with this learn about the best person in charge A1 Amen together![pray 🙏](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f64f.png)
![pray 🙏](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f64f.png)
![people_hugging 🫂](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1fac2.png)